Skip to main content

Medable

Category: AI in Healthcare

A global decentralized clinical trial (DCT) platform that leverages agentic AI to automate complex research workflows and accelerate drug development. Medable was founded in 2015. The company is led by Michelle Longmire. Based in Palo Alto, USA. Team size: 501-1000. Total funding raised: $521,000,000. Latest round: Series D. Key investors include Blackstone Growth, Tiger Global Management, GSR Ventures, Sapphire Ventures, PPD (Thermo Fisher Scientific).

Founded
2015
Headquarters
Palo Alto, USA
Team size
501-1000
Total funding
$521,000,000

Value proposition

Reduces clinical trial timelines from months to hours through no-code automation, improves patient diversity via decentralized access, and eliminates administrative bottlenecks using human-in-the-loop AI agents.

Products and solutions

Agent Studio (Agentic AI workflow platform), TMF Agent (Automated Trial Master File processing), Medable Studio (No-code eCOA and trial configuration builder), Decentralized Clinical Trial (DCT) Platform, eCOA & eConsent (Electronic outcomes and consent management), Televisit (Virtual clinical visits), Medable SDK (Digital biomarker and device integration)

Unique value

Pioneered the 'Agentic AI' category for clinical trials, moving beyond simple data capture to autonomous AI agents that manage regulatory documentation and trial operations.

Target customer

Pharmaceutical sponsors, Contract Research Organizations (CROs), biotechnology firms, and clinical research sites.

Industries served

Life Sciences, Pharmaceuticals, Biotechnology, Healthcare Technology

Technology advantage

A unified, modular global architecture that combines no-code configuration with 'human-in-the-loop' AI, allowing for rapid deployment across diverse regulatory environments (e.g., CNIL approval in the EU).

How they differentiate

Pioneering 'Agentic AI' with the Agent Studio platform, allowing for autonomous automation of Trial Master Files (TMF) and clinical workflows, combined with a no-code environment for rapid trial deployment.

Main competitors

Science 37, THREAD, Veeva Systems

Key partnerships

PPD (Part of Thermo Fisher Scientific), CVS Health (MinuteClinic trial access), Syneos Health, Google Cloud (AI infrastructure), Withings (Connected health devices), Oracle and Cognizant (Strategic technology integration)

Notable customers

CVS Health, PPD, Syneos Health, Withings, Various Top 20 Pharma companies

Major milestones

Achieved $2.1B valuation in 2021, Named to CNBC Disruptor 50 list multiple times, Partnered with CVS Health to increase clinical trial access via MinuteClinics, Launched the industry's first Agentic AI platform for clinical trials (Agent Studio) in early 2026

Growth metrics

Achieved unicorn status with a $2.1B valuation; reported 80% revenue growth in enterprise SaaS adoption as of 2024.

Market positioning

Market-leading unicorn in the Decentralized Clinical Trial (DCT) space, positioned as a premium enterprise SaaS provider for top-tier pharmaceutical companies.

Geographic focus

Global operations with primary focus on North America and Europe (maintaining high regulatory compliance standards like CNIL in the EU).

Patents and IP

Holds multiple patents related to digital biomarkers, clinical trial data processing, and technology-enabled patient care (led by physician-scientist CEO Dr. Michelle Longmire).

About Michelle Longmire

Dr. Michelle Longmire is a Stanford-trained physician-scientist and dermatologist. Before founding Medable, she completed her residency and clinical research at the Stanford University School of Medicine, where she focused on the intersection of technology and healthcare. She has authored over 20 peer-reviewed publications and holds multiple patents. Under her leadership, Medable has grown into a unicorn valued at over $2 billion, pioneering the decentralized clinical trial (DCT) category.

Official website: